Event focuses on science of skin barrier damage and repair in pediatric patients with atopic dermatitis, or “eczema”
SANTA BARBARA, CA / ACCESSWIRE / October 12, 2023 / Global Parents for Eczema Research (GPER) is pleased to announce its annual research symposium highlighting impactful research related to the treatment and prevention of eczema in children to be held virtually on November 9, 2023. This year’s event will highlight advances in our understanding of the skin barrier and how damage to it can lead to eczema.
“We’re thrilled to bring together these distinguished researchers who are illuminating the causes of eczema and finding ways to repair the skin barrier to prevent it,” said Korey Capozza, Executive Director of GPER. “This event brings together diverse stakeholders to share ideas and discuss opportunities for collaboration to benefit children with eczema,” she continued.
Topics and speakers include:
Dr. Jeffrey McBride, GPER Board Member, will kick off the event, and GPER Founder and Executive Director, Korey Capozza, will moderate the symposium.
Learn more and register to attend.
# # #
About Global Parents for Eczema Research (GPER): GPER is a global, grassroots, nonprofit organization whose mission is to end the suffering of children with eczema by advancing research and empowering families. GPER serves parents struggling with the demands of managing eczema through its free caregiver support program. For more information: www.parentsforeczemaresearch.com
Contact Information
Korey Capozza
Executive Director
korey@parentsforeczemaresearch.com
805-232-4479
SOURCE: Global Parents for Eczema Research
View source version on accesswire.com:
https://www.accesswire.com/792499/symposium-to-highlight-advances-in-skin-barrier-research
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…